Table 5.
Univariate and multivariate Cox proportional hazard analysis of APLN expression and DSS for patients with cervical cancer in the TCGA cohort.
| Characteristics | Total (N) | HR (95% CI) univariate analysis | p Value univariate analysis | HR (95% CI) multivariate analysis | p Value multivariate analysis |
|---|---|---|---|---|---|
| N stage (N1 vs N0) | 191 | 3.303 (1.446–7.541) | 0.005 a | 2.970 (1.187–7.430) | 0.02 a |
| Clinical stage (stage II, stage III and stage IV vs stage I) | 293 | 1.608 (0.941–2.749) | 0.082 | ||
| Radiation therapy (yes vs no) | 300 | 1.772 (0.891–3.522) | 0.103 | ||
| Histological type (squamous vs adenosquamous cell carcinoma) | 300 | 0.956 (0.467–1.958) | 0.901 | ||
| Menopause status (post vs pre and peri) | 228 | 1.233 (0.678–2.243) | 0.493 | ||
| Histologic grade (G3 and G4 vs G1 and G2) | 269 | 0.955 (0.530–1.720) | 0.877 | ||
| Age (>50 vs ≤50) | 300 | 1.333 (0.780–2.278) | 0.292 | ||
| PIK3CA status (Mut vs WT) | 282 | 1.097 (0.606–1.989) | 0.759 | ||
| Primary therapy outcome (PD, SD, and PR vs CR) | 217 | 16.934 (8.629–33.235) | <0.001 a | 10.497 (3.470–31.753) | <0.001 a |
| Race (Asian and Black or African American vs White) | 257 | 0.770 (0.344–1.724) | 0.526 | ||
| APLN (high vs low) | 300 | 2.178 (1.236–3.838) | 0.007 a | 5.134 (1.854–14.216) | 0.002 a |
CI: confidence interval; CR: complete response; HR: hazard ratio; PD: progressive disease; PR: partial response; SD: stable disease.
a
Statistically significant.